Christina Kalderén, Oxcia’s Preclinical Director gave an update on Oxcias´s OXC-201 program “Harnessing Oxidative Stress & DNA Damage Response Pathways for Innovative Antifibrotic Therapies. Examining the potential of OXC-201, an OGG1 inhibitor, as a novel therapy for idiopathic lung fibrosis at the Antifibrotic Drug Development Summit (AFDD) in Boston 21-22 of November. The 8th AFDD summit dove into the latest breakthroughs, from discovery and novel targets to preclinical models and early-stage clinical trials, offering unparalleled insights to accelerate antifibrotic therapy development.
About OXC-201
OXC-201 is a small molecule inhibitor of OGG1, a potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), other fibrotic conditions and inflammatory diseases. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models. OXC-201 is patent protected and Oxcia AB has exclusive rights under the patent to develop and commercialize OXC-201.
The EIC (European Innovation Council) has awarded Oxcia AB a grant of 2.5 million euros within the EIC-Transition program which finances the next phase of the development of OXC-201.